Sean K. Kelley
Publications by Year
Research Areas
Retinoids in leukemia and cellular processes, Cell death mechanisms and regulation, Monoclonal and Polyclonal Antibodies Research, Immunotherapy and Immune Responses, Toxic Organic Pollutants Impact
Most-Cited Works
- → Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions(2001)693 cited
- → Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer(2005)536 cited
- → Preclinical Studies to Predict the Disposition of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Humans: Characterization of in Vivo Efficacy, Pharmacokinetics, and Safety(2001)442 cited
- → Targeting death receptors in cancer with Apo2L/TRAIL(2004)369 cited
- → Role of Raf Kinase in Cancer: Therapeutic Potential of Targeting the Raf/MEK/ERK Signal Transduction Pathway(2006)355 cited
- → Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma1(2006)217 cited
- → Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer(2016)134 cited
- → Plasma Thyroid Hormone Kinetics Are Altered in Iron-Deficient Rats(1998)106 cited
- → Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774)(2004)83 cited
- → TISSUE DISTRIBUTION, STABILITY, AND PHARMACOKINETICS OF APO2 LIGAND/TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND IN HUMAN COLON CARCINOMA COLO205 TUMOR-BEARING NUDE MICE(2004)70 cited